Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TDM-812
- Development stage
- Unknown
- Lead developer
- 3-D Matrix
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Hydrogel Systems → Drug Delivery Systems, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
TDM-812 is an investigational RNA interference (RNAi) therapeutic developed by 3-D Matrix, Ltd. for the treatment of refractory breast cancer. It consists of a small interfering RNA (siRNA) targeting **Ribophorin II (RPN2)**, formulated within a self-assembling peptide hydrogel (0.5% AGK/glucose). RPN2 is a key component of the oligosaccharyltransferase complex that facilitates the N-glycosylation of P-glycoprotein; its overexpression is linked to multidrug resistance and poor clinical outcomes in breast cancer patients. By silencing RPN2, TDM-812 aims to reduce the stability and activity of P-glycoprotein, thereby restoring the sensitivity of cancer cells to chemotherapeutic agents like anthracyclines and taxanes. The drug is designed for weekly **intratumoral** administration, utilizing the hydrogel platform to provide localized delivery and sustained release of the siRNA within the tumor.
- Other names
- RPN2 siRNARPN-2 siRNARPN 2 siRNARPN2 siRNA/AGK
02
Targets
Ribophorin II messenger RNA
Beyond the preview
Go deeper on TDM-812.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TDM-812.